8 min listen
Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years
Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years
ratings:
Length:
8 minutes
Released:
Jan 9, 2012
Format:
Podcast episode
Description
Interview with Samuel G. Jacobson, MD, PhD, author of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years
Released:
Jan 9, 2012
Format:
Podcast episode
Titles in the series (100)
Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years: Interview with Samuel G. Jacobson, MD, PhD, author of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years by JAMA Ophthalmology Author Interviews